Wall Street brokerages predict that Synlogic (NASDAQ:SYBX) will report earnings per share (EPS) of ($0.75) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Synlogic’s earnings, with the lowest EPS estimate coming in at ($1.02) and the highest estimate coming in at ($0.62). Synlogic reported earnings per share of ($0.84) during the same quarter last year, which indicates a positive year over year growth rate of 10.7%. The business is expected to issue its next earnings results on Tuesday, May 8th.
According to Zacks, analysts expect that Synlogic will report full year earnings of ($2.98) per share for the current financial year, with EPS estimates ranging from ($3.88) to ($2.35). For the next financial year, analysts expect that the company will report earnings of ($3.09) per share, with EPS estimates ranging from ($3.96) to ($2.34). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side analysts that that provide coverage for Synlogic.
Synlogic (NASDAQ:SYBX) last posted its earnings results on Tuesday, March 20th. The biotechnology company reported ($0.74) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.07. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.11 million.
SYBX stock opened at $11.38 on Thursday. Synlogic has a fifty-two week low of $8.76 and a fifty-two week high of $23.00. The company has a quick ratio of 9.82, a current ratio of 9.82 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $224.07, a P/E ratio of -1.94 and a beta of 2.21.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Spark Investment Management LLC purchased a new stake in shares of Synlogic during the fourth quarter valued at $105,000. Deutsche Bank AG boosted its stake in shares of Synlogic by 204.0% during the fourth quarter. Deutsche Bank AG now owns 19,672 shares of the biotechnology company’s stock valued at $190,000 after purchasing an additional 13,200 shares during the period. Renaissance Technologies LLC purchased a new stake in shares of Synlogic during the fourth quarter valued at $191,000. Finally, Artal Group S.A. purchased a new stake in shares of Synlogic during the fourth quarter valued at $5,335,000. 55.53% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This piece was originally published by Chaffey Breeze and is the property of of Chaffey Breeze. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.chaffeybreeze.com/2018/04/17/0-75-eps-expected-for-synlogic-sybx-this-quarter.html.
Synlogic Company Profile
Synlogic, Inc develops synthetic biotic medicines for the treatment of patients with urea cycle disorder and phenylketonuria. The company is based in Cambridge, Massachusetts.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Synlogic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic and related companies with MarketBeat.com's FREE daily email newsletter.